Maa: Etelä-Afrikka
Kieli: englanti
Lähde: South African Health Products Regulatory Authority (SAHPRA)
Bm_squib
CAPOTEN HS TABLETS CAPOTEN 25 mg TABLETS SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): CAPOTEN HS TABLETS CAPOTEN 25 mg TABLETS COMPOSITION CAPOTEN tablets contain 12,5, or 25 mg of D-3-mercapto-2- methylpropanoyl-L-proline ( captopril ). PHARMACOLOGICAL CLASSIFICATION Category A 7.1 Vasodilators, hypotensive medicine. PHARMACOLOGICAL ACTION CAPOTEN (captopril) is an inhibitor of angiotensin converting enzyme (ACE) which converts angiotensin I to angiotensin II, a potent endogenous vasoconstrictor substance. The mechanism of action of CAPOTEN (captopril) has not yet been fully elucidated. Its effects appear to result primarily from suppression of the renin-angiotensin-aldosterone system resulting in decreased serum concentrations of angiotensin II and aldosterone. However, there is no consistent correlation between renin levels and response to the drug. The reduction of angiotensin II leads to decreased aldosterone secretion, and, as a result, increases in serum potassium may occur along with sodium and fluid loss. ACE is identical to "bradykininase", and may also interfere with the degradation of bradykinin, which increases the concentration of bradykinin or prostoglandin E 2 . CAPOTEN (captopril) is rapidly absorbed from the gastrointestinal tract; the peak blood level occurs at about one hour. The average minimal absorption is approximately 75 percent. The presence of food in the gastro-intestinal tract reduces absorption by about 30 to 40 percent. Only 25 to 30 percent of the drug is bound to plasma proteins. The apparent elimination half-life in blood is about 4 hours for the 4 to 12-hour time interval. The half-life of unchanged drug is approximately 2 hours. About 75 percent of a dose of CAPOTEN is excreted in the urine (of which 50 percent is unchanged drug an Lue koko asiakirja